For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Abatacept - Rheumatoid arthritis
PAD Profile : Abatacept - Rheumatoid arthritis Important
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Certolizumab pegol
- Etanercept
- Golimumab
- Penicillamine
- Rituximab
- Tocilizumab
- Adalimumab
- Sodium aurothiomalate
- Infliximab
- Baricitinib
- Tofacitinib
- Sarilumab
- Filgotinib
- Upadacitinib
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathways (moderate and severe).
Abatacept is NON-FORMULARY for moderate disease.
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agrees with the recommendations made in NICE TA715.
Abatacept for moderately active Rheumatoid Arthritis was not recommended by NICE and will be given a NON-FORMULARY traffic light status for this indication. The current treatment pathway is attached below.